Valuation : Legend Biotech Corporation

Market Cap 3.85B 3.32B 3.11B 2.84B 5.35B 368B 5.37B 36.92B 14.41B 186B 14.46B 14.15B 616B P/E 2026 *
2,442x
P/E 2027 * 22.5x
Enterprise Value 2.92B 2.51B 2.36B 2.15B 4.05B 279B 4.06B 27.95B 10.9B 141B 10.95B 10.71B 466B EV / Sales 2026 *
2.03x
EV / Sales 2027 * 1.53x
Free-Float
98.75%
Yield 2026 *
-
Yield 2027 * -
1 day+1.43%
1 week-4.49%
Current month+7.82%
1 month+7.82%
3 months-21.60%
6 months+11.98%
Current year-8.00%
1 week 19.71
Extreme 19.706
21.67
1 month 18.39
Extreme 18.39
23.24
Current year 16.24
Extreme 16.24
37.5
1 year 16.24
Extreme 16.24
37.5
3 years 16.24
Extreme 16.24
72.38
5 years 16.24
Extreme 16.24
77.32
10 years 16.24
Extreme 16.24
77.32
Manager TitleAgeSince
Chief Executive Officer 54 2026-07-23
Director of Finance/CFO - 2025-08-17
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 2020-11-05
Director/Board Member 69 2020-04-30
Director/Board Member 64 2020-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 Free

Chief Executive Officer

4,908 0.0017%
7/24/26 Other

Chief Executive Officer

30,234 0.0105%
6/30/26 Don

Chief Executive Officer

-3,382 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+1.61%-4.49%-41.55%-71.16% 3.85B
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.19%+1.32%+44.54%+88.38% 64.97B
-3.57%-4.24%+47.11%+5.60% 26.51B
+1.17%-3.21%-17.41%+448.20% 25.89B
-0.29%-9.91%+1.01%-15.95% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-3.36%-7.58%+9.47%+535.81% 15.69B
-0.28%-0.71%+45.68%+141.92% 13.49B
Average -2.00%-4.22%+41.39%+157.93% 28.58B
Weighted average by Cap. -2.12%-3.57%+46.70%+141.80%

Financials

2026 *2027 *
Net sales 1.43B 1.24B 1.16B 1.06B 1.99B 137B 2B 13.75B 5.36B 69.19B 5.38B 5.27B 229B 1.81B 1.56B 1.46B 1.34B 2.52B 173B 2.52B 17.35B 6.77B 87.34B 6.8B 6.65B 290B
Net income -12.85M -11.07M -10.38M -9.48M -17.85M -1.23B -17.91M -123M -48.05M -620M -48.24M -47.19M -2.06B 228M 196M 184M 168M 316M 21.75B 317M 2.18B 851M 10.98B 854M 836M 36.4B
Net Debt -936M -807M -757M -691M -1.3B -89.5B -1.31B -8.98B -3.5B -45.18B -3.52B -3.44B -150B -1.08B -930M -872M -796M -1.5B -103B -1.5B -10.35B -4.04B -52.08B -4.05B -3.96B -173B
Logo Legend Biotech Corporation
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Employees
3,200
Date Price Change Volume
26-08-31 US$20.05 +0.86% 384,651
26-08-28 US$19.88 -3.02% 1,151,199
26-08-27 US$20.50 -0.87% 1,016,199
26-08-26 US$20.68 -2.91% 925,072
26-08-25 US$21.30 +1.72% 1,408,246
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
19.88USD
Average target price
49.25USD
Spread / Average Target
+147.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LEGN Stock